Head-to-head evidence
Bepranemab vs NIO752
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Alzheimer's Disease
Shared mechanism: Tau (monoclonal antibody) · full Alzheimer's Disease pipeline
Bepranemab
Developed by UCB
NCT04867616 · Phase 2 · completed
The study randomized 466 participants to two bepranemab dose groups or placebo and used quadruple blinding of participants, care providers, investigators, and outcome assessors. Its primary clinical endpoint was change in CDR-SB at Week 80, but whether this endpoint was met cannot be determined because results are not posted.
NIO752
Developed by Novartis
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Bepranemab's landscape · NIO752's landscape